 |
Bioavailability/bioequivalence studies according to the CPMP Note for Guidance and the FDA Guidance for Industry
|
 |
Pharmacokinetic investigations (LADME)
|
 |
Interaction studies (drug-drug and drug-food)
|
 |
Studies with pharmacodynamic surrogate parameters and biomarkers
|
 |
Investigations in special populations, e.g. patients with impaired organ function
(renal or hepatic insufficiency), post-menopausal women
|
 |
Studies in symptomatic patients, e.g. with hyperlipoproteinemia, diabetes mellitus or
oncological indications
|
 |
Studies on local tolerability (e.g. skin irritation) according to US-FDA standards
|
 |
Investigations on in-vitro/in-vivo-correlations (IVIVC)
|
 |
Absorption-site studies by use of intestinal-tube technique
|
 |
Magnetic Marker Monitoring for gastro-intestinal Imaging
(PDF-folder)
|
 |
Characterization of drug substances and dosage forms
|
 |
Performance of medicinal products administered to patients
|
 |
Conceptional consultation: from development concept to registration
|
 |
CTD: Clinical Overview, Analytical Overall Summary
|
 |
Special expert statements, e.g. biowaivers, acceptance criteria, study results
|